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CASE REPORT
We described here a patient who had two lung masses. Although the two masses had the same histology and a
similar good response to initial chemotherapy with gemcitabine and carboplatin, the response to pemetrexed as a
second-line treatment was different after re-growth of the tumors. These two lung masses could have originated
from different clones or they could have progressed through different paths of molecular pathogenesis after
metastasis, which would lead to different tumor characteristics, including their chemosensitivity. Regardless of
their pathogenetic mechanisms, it seems important to recognize that tumors with the same histology that develop
in one patient can have different responses to drugs. (Korean J Intern Med 2010;25:213-216)
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INTRODUCTION
Multiple synchronous lung carcinomas are not uncommon
and the incidence of this malady ranges from 1% to 7% [1].
Because the prognosis has generally been poor for cases
with lung metastases [2], it is critical to distinguish syn-
chronous primary cancer from intrapulmonary metastases.
Martini and Melamed [3] indicated that synchronous lung
cancer requires the following criteria for diagnosis: 1) the
two tumors must be anatomically distinct and separate, 2)
the tumors are historically different, and 3) if the tumors’
histology is of the same type, then each tumor should have
its own original site, and there should be no cancer in the
lymphatic vessels common to both, and no metastasis
from another organ. However, it is often not so easy to
differentiate multiple primary cancers from single primary
cancer with metastasis, and especially in cases where two
lesions have the same histology. We report here on a
unique case that had two distinct lung masses with the
same location, the same histology and a similar good
response to initial chemotherapy with gemcitabine and
carboplatin, but these tumors showed a different response
to pemetrexed as a second-line treatment.
CASE REPORT
A 74-year-old woman came to our hospital for evaluation
of her hemoptysis. Two distinct 3 cm-sized lung masses in
the left upper lobe were found on the chest PA (Fig. 1).
Squamous cell carcinoma was diagnosed by trans-thoracic
needle biopsy of the lower mass. Although the other mass
could have been a double primary carcinoma, further
diagnostic tests were not done because the patient did not
want them at that time. There was also enlargement of
multiple mediastinal lymph nodes, suggesting that any
benefit from radical treatment would not be great. After
four cycles of chemotherapy with gemcitabine (1,000
mg/m2, days 1 and 8, every 3 weeks) and carboplatin (area
under the curve: 6, day 1, every 3 weeks), the size of the
two lung masses was decreased and so this was deemed a
partial response. During the subsequent follow-up, the
lung masses were again increased in size and she received
second-line chemotherapy with two cycles of pemetrexed
(500 mg/m2, day 1, every 3 weeks). After completion of
chemotherapy with pemetrexed, the lower mass was
markedly resolved while the upper mass did not respond
(Fig. 2). Biopsy to the other mass was performed to214 The Korean Journal of Internal Medicine Vol. 25, No. 2, June 2010
determine whether it was a double primary carcinoma.
However, the histology was almost same as the previously
obtained specimen, and this made it difficult to
differentiate the mass from metastasis (Fig. 3).
Considering her age and performance, we decided not to
administer further chemotherapy and so we
recommended regular follow-up.  
DISCUSSION
The rate of detecting synchronous multiple lung tumors
has recently increased due to the advances in diagnostic
imaging modalities such as multi-slice spiral computed
tomography and positron emission tomography scanning.
Most reported cases of synchronous tumors in the lung
have been shown to have the same histologic type. Among
the possible tumor combinations reported in the medical
literature, squamous cell carcinoma was by far the most
common [1,3,4]. Thus, having the same cell type cannot
exclude the possibility of synchronous double primary
carcinoma. Various methods like DNA flow cytometry and
DNA marker analysis can provide information about the
loss of heterozygosity, and this might be useful to
accurately identify genetic difference of two masses that
have the same histology [1,5]. In our case, we could not
carry these procedures out because the amounts of the
procured tissue samples were too small.
The two lung masses of this patient could have originated
from different clones or they could have progressed
through different paths of molecular pathogenesis after
metastasis, which would lead to different tumor character-
istics, including their chemosensitivity. Regardless of their
pathogenetic mechanisms, it seems important to recognize
that tumors with the same histology that develop in one
patient can have different responses to drugs. We previously
reported on another case of multiple primary lung cancers
that had different responses to gefitinib. In that case, the
sensitivity to gefitinib was related with mutations of
epidermal growth factor receptor-tyrosine kinase [6]. 
Pemetrexed is a multi-targeted antifolate that inhibits
several folate-dependent enzymes involved in both purine
Figure 1. The initial chest radiograph shows two round lung
masses in the left upper lobe.
Figure 2. (A) Two lung masses in the left upper lobe. (B) The masses after treatment with gemcitabine and carboplatin. (C) Increased
size of the masses during follow-up. (D) Different response of the two masses to pemetrexed.
A B
C Dand pyrimidine synthesis. The overall response rate was
9.1% for pemetrexed in a randomized phase III trial of
pemetrexed versus docetaxel in patients with non-small
cell lung cancer and who had been previously treated with
chemotherapy [7]. In 2007, there was a report of the in
vitro chemosensitivity of freshly explanted tumor cells to
pemetrexed. In that study, a low level of thymidylate
synthase (TS) and the mrp4 gene expression significantly
correlated with the chemosensitivity to pemetrexed, and
the predictive value of TS and the mrp4 gene expression
was independent of the tumor type [8]. This might con-
tribute to explaining the different responses to pemetrexed
in our case, although this needs to be confirmed by further
investigations. 
Predicting the chemosensitivity of individual patients is
important for improving the efficacy of cancer treatment
and avoiding unwanted side effects and the economical
expense of ineffective agents. However, this is quite
challenging because drug responses reflect both the
characteristics of the targeted cells, the mode of drug
delivery and/or the host’s metabolism. Although several
genes have been reported to determine the response to
drugs [9], this seems to be useful in only very limited
situations. In addition, several attempts have been made
to predict drug sensitivity with transcriptional profiling by
using c-DNA microarray, proteomic profiling, in vitro
culture assay etc [9-11]. Even though previous studies
have shown some feasibility to achieve this prediction of
response, the practical application to actual clinical cases
still seems to have a long way to go.
We currently don’t know what determines the response
to pemetrexed. However, we believe this can be clarified in
the near future via efforts to gain a better understanding
about carcinogenesis and to find more molecular factors
that can affect the sensitivity to drugs. Gaining such
knowledge may lead to a new era of individualized/
tailored cancer therapy. 
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